东亚药业(605177.SH)：2025年度预亏7500万元至9000万元

Core Viewpoint - East Asia Pharmaceutical (605177.SH) expects a significant net loss for the fiscal year 2025, indicating potential challenges ahead for the company [1] Financial Projections - The company anticipates a net profit attributable to shareholders of between -90 million and -75 million yuan for the year 2025 [1] - The projected net profit, excluding non-recurring gains and losses, is expected to range from -102 million to -87 million yuan for the same period [1]